Orchid Pharma (ORCHPHARMA) | Stock Overview & Key Data
Orchid Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹716.80
High: ₹748.00
on October 3, 2025
52 Week Range
Low: ₹603.80
High: ₹1,997.40
on May 30, 2025
on January 3, 2025
All-Time High: ₹2,654.25 on April 5, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR37.3B
EPS
16.81
P/E Ratio (TTM)
42.84
Forward P/E
22.31
P/B Ratio
2.88
PEG Ratio
-0.87
Div. Yield
N/A
ROE
7.86%
Beta
1.725
Debt to Equity
13.78
Financial Highlights
Profitability
Gross Margin
42.83%
Operating Margin
3.19%
Profit Margin
10.02%
Returns and Earnings
Return on Assets (TTM)
5.90%
Return on Equity (TTM)
7.86%
EBITDA
INR1.4B
Net Income (TTM)
INR852.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR167.68
Quarterly Revenue Growth (YoY)
-29.20%
Quarterly Earnings Growth (YoY)
-49.20%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma ORCHPHARMA | 37.30B Small-cap | -2.46% | -1.19% | -2.62% | -8.02% | -60.77% | -43.92% | 118.62% | 13,113.76% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | 4.66% | -1.86% | -3.66% | -13.43% | -14.34% | 71.30% | 219.01% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | -4.58% | -6.29% | -16.72% | 2.89% | -5.98% | 5.24% | 52.85% | 79.00% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -6.65% | -0.56% | -18.38% | 69.66% | 61.86% | 45.66% | 184.80% | 304.79% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | -5.64% | 3.08% | 3.92% | 42.25% | 7.15% | -5.48% | -1.60% | -50.42% |
Ownership & Short Interest
Insider Ownership
69.84%
Institutional Ownership
18.33%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
242K
Average 90-Day Volume
112K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ORCHPHARMA's 52-week high and low?
- In the last 52 weeks, Orchid Pharma reached a high of ₹1,997.40 (on January 3, 2025) and a low of ₹603.80 (on May 30, 2025).
- What is the market cap and P/E ratio for ORCHPHARMA?
- Curious about Orchid Pharma's size and valuation? Its market capitalization stands at 37.30B. When it comes to valuation, the P/E ratio (trailing twelve months) is 42.84, and the forward P/E (looking ahead) is 22.31.
- Does ORCHPHARMA pay dividends? If so, what's the yield?
- As for dividends, Orchid Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Orchid Pharma's main competitors or similar companies to consider before investing?
When looking at Orchid Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.34% 71.30% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 5.24% 52.85% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 45.66% 184.80% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -5.48% -1.60% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Orchid Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Orchid Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.86%, the Debt to Equity ratio from the most recent quarter is 13.78, and its Gross Profit Margin stands at 42.83%.
- What is the recent revenue and earnings growth for ORCHPHARMA?
- Looking at Orchid Pharma's growth, its revenue over the trailing twelve months (TTM) was INR9B. Compared to the same quarter last year (YoY), quarterly revenue grew by -29.20%, and quarterly earnings saw a YoY growth of -49.20%.
- How much of ORCHPHARMA stock is held by insiders and institutions?
- Wondering who owns Orchid Pharma stock? Company insiders (like executives and directors) hold about 69.84% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 18.33%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.